ducovest

EXEL:NSD-Exelixis Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 36.17

Change

0.00 (0.00)%

Market Cap

USD 9.97B

Volume

1.87M

Analyst Target

USD 30.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Company Website : https://www.exelixis.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

 USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

 USD 65.38B
ARGX argenx NV ADR

N/A

 USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD 32.75B
SMMT Summit Therapeutics PLC

N/A

 USD 27.07B
ONC BeiGene, Ltd.

N/A

 USD 26.35B
RPRX Royalty Pharma Plc

N/A

 USD 18.40B
INSM Insmed Inc

N/A

 USD 11.84B
INCY Incyte Corporation

N/A

 USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

 USD 11.29B

ETFs Containing EXEL

XDNA:CA iShares Genomics Immunolo.. 5.20 % 0.00 %

N/A

 CAD 4.62M
HLTH:AU VanEck Global Healthcare .. 3.15 % 0.00 %

N/A

 USD 0.06B
FHH-F:CA First Trust AlphaDEX U.S... 2.43 % 0.00 %

N/A

 CAD 0.01B
RAYD Rayliant Quantitative Dev.. 2.17 % 0.00 %

N/A

 USD 0.08B
AFMC First Trust Active Factor.. 1.33 % 0.00 %

N/A

 USD 0.06B
JMEE JPMorgan Market Expansion.. 0.60 % 0.00 %

N/A

 USD 1.55B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

 CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

 USD 0.89B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

N/A

 USD 0.10B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

N/A

 USD 14.84B
MUSC:CA Manulife Multifactor U.S... 0.00 % 0.62 %

N/A

 CAD 3.66M
2B77:XETRA iShares Ageing Population.. 0.00 % 0.00 %

N/A

 USD 0.50B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

 USD 8.18M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

 USD 8.18M
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.62% 83% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.62% 83% B 82% B
Trailing 12 Months  
Capital Gain 69.26% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.26% 92% A 92% A
Trailing 5 Years  
Capital Gain 34.66% 84% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.66% 84% B 53% F
Average Annual (5 Year Horizon)  
Capital Gain 10.02% 63% D 66% D+
Dividend Return 10.02% 63% D 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.73% 91% A- 65% D
Risk Adjusted Return 37.48% 90% A- 71% C-
Market Capitalization 9.97B 98% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.